Clinical TrialMay 8, 2026, 07:32 AM
Plus Therapeutics REYOBIQ Phase 1 LM trial shows 9-month median survival
AI Summary
Plus Therapeutics announced the presentation of positive Phase 1 ReSPECT-LM trial data for REYOBIQ ™ (rhenium Re186 obisbemeda) at the 2026 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting. The data highlighted encouraging survival outcomes, robust anti-tumor activity, and a favorable safety profile for patients with leptomeningeal metastases. Patients treated at the recommended Phase 2 dose achieved a median overall survival of approximately 9 months, significantly exceeding historical survival rates of 2-6 months. Translational analyses also indicated potential immune remodeling, supporting future combination strategies, and the multiple-dose trial is currently enrolling patients.
Key Highlights
- Phase 1 ReSPECT-LM trial data for REYOBIQ ™ presented at the 2026 AANS Annual Scientific Meeting.
- Median overall survival of approximately 9 months at the recommended Phase 2 dose.
- Historical survival for leptomeningeal metastases is approximately 2-6 months.
- Demonstrated robust anti-tumor activity, including high rates of circulating tumor cell reduction.
- Favorable safety and tolerability profile, supporting advancement to later-stage clinical development.
- Highly targeted radiation delivery with a target-to-off-target absorbed dose ratio exceeding 100:1.
- Translational analyses suggest REYOBIQ ™ may induce immune remodeling, activating CD8+ T cells.
- The ReSPECT-LM Phase 1 Multiple Dose trial is currently underway and enrolling patients.